Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
THRB knockout activated retinoic acid pathway, leading to progestin resistance. CANA targeted RARβ and RXRA, downregulated CRABP2, restored BAX levels, and counteracted progestin resistance. The combination of CANA and MPA presented a novel strategy for alleviating progestin resistance and enhancing clinical efficacy.
Authors
- Jieyun Zhou
- Guoting Li
- Baichun Hu (ORCID: https://orcid.org/0000-0001-8959-6979)
- Qiaoying Lv (ORCID: https://orcid.org/0000-0003-3610-2538)
- Ruihua Zhong (ORCID: https://orcid.org/0000-0001-8682-5203)
- Yan Zhu (ORCID: https://orcid.org/0000-0001-7206-2612)
- Qicheng Ni (ORCID: https://orcid.org/0000-0002-9033-9328)
- Suqing Qu
- Xiaojun Chen (ORCID: https://orcid.org/0000-0002-5493-1500)
- Yulong Wang (ORCID: https://orcid.org/0000-0002-0514-1131)
- Wenjie Yang (ORCID: https://orcid.org/0000-0002-1013-2678)
- Ye Yang (ORCID: https://orcid.org/0000-0001-7711-2121)
Institutions
- Shenyang Pharmaceutical University (CN)
- Tongji University (CN)
- Fudan University (CN)
- Shanghai Institute of Planned Parenthood Research (CN)
- Shanghai Tenth People's Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-30
- DOI
- https://doi.org/10.3389/fphar.2025.1573032
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission